Introduction Beijing Ruicy Gene Therapy Institute for Rare Diseases, commonly referred to as RDGT Institute, was formally established in September 2014 as a non-profit scientific research organization registered in Beijing under the Bureau of Civil Affairs. The Institute operates as a private non-enterprise entity dedicated to the public good in both science and industry, focusing primarily on advancing the development of gene therapies for rare diseases and harnessing scientific advancements to serve the rare disease community. As the pioneering non-profit research entity in China to concentrate exclusively on gene therapy for rare ailments, the RDGT Institute is committed to conducting basic research in gene therapy for rare diseases, developing related pharmaceuticals, and facilitating the progression of these treatments into clinical trials. |